--- schema_version: "secwatch.filing_event.v1" accession: "0001171843-26-003877" form_type: "8-K" ticker: "HBIO" cik: "0001123494" company_name: "HARVARD BIOSCIENCE INC" filed_at: "2026-06-02T20:01:17+00:00" generated_at: "2026-06-02T20:02:12.952222+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.4 confidence: "high" source: SEC EDGAR --- # Stockholders approve 400,000-share increase in 2021 Incentive Plan and amendment to ESPP ## Summary - Stockholders elected John Duke and Katherine A. Eade as Class II directors for three-year terms. - Ratified Grant Thornton LLP as independent auditor for FY2026; 2,781,705 votes for, 13,975 against. - Non-binding advisory vote approved named executive officer compensation: 1,768,695 for, 57,111 against. - Amended ESPP increases authorized shares from 310,000 to 1,900,000 (approx. 1.59M share increase). - Amended 2021 Incentive Plan increases authorized shares by 400,000 (from 646,520 available as of Dec 2025). ## SEC filing metadata - accession: 0001171843-26-003877 - form_type: 8-K - ticker: HBIO - cik: 0001123494 - company_name: HARVARD BIOSCIENCE INC - filed_at: 2026-06-02T20:01:17+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.4 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/f8k_060226.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001171843-26-003877 - JSON: https://secwatch.observer/filing/0001171843-26-003877.json - Plain text: https://secwatch.observer/filing/0001171843-26-003877.txt ## Source-grounded claims - claim_id: 18191a756ad9442e92e8b1d10d9d8a0a0023c12f claim: HARVARD BIOSCIENCE INC shareholders approved Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan at the 2026-06-02 meeting. evidence_excerpt: Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538 evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm - claim_id: 646754887239498f802fb15235e998235046c7e6 claim: HARVARD BIOSCIENCE INC shareholders approved Election of two Class II Directors at the 2026-06-02 meeting. evidence_excerpt: On June 2, 2026, the Company held its Annual Meeting, at which the Company’s stockholders voted on five proposals that are described in detail in the Definitive Proxy Statement. The voting results for each of the proposals are reported below. Proposal 1 - Election of Directors The Company’s stockholders elected two Class II Directors for three-year terms, such terms to continue until the annual meeting of stockholders in 2029 and until such Directors’ successors are duly elected and qualified or until his or her earlier resignation or removal: Name Votes For Votes Withheld Broker Non-Votes John Duke 1,800,288 28,703 970,538 Katherine A. Eade 1,680,982 148,009 970,538 evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm - claim_id: 883350bf0054641d528b952b896a550b74e3741c claim: HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers at the 2026-06-02 meeting. evidence_excerpt: Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved the compensation of the Company’s named executive officers by a non-binding advisory vote, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,768,695 57,111 3,185 970,538 evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm - claim_id: 93d1eab07ef3d0ad79dd5d7d3bebeaeff881e887 claim: HARVARD BIOSCIENCE INC shareholders approved Approval of the Amended and Restated 2021 Incentive Plan at the 2026-06-02 meeting. evidence_excerpt: Proposal 5 – Approval of the Amended and Restated 2021 Incentive Plan The Company’s stockholders approved the Amended and Restated 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,131,261 680,030 17,700 970,538 evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm - claim_id: ffc5262c3a4c3101da0e9b7e475d69fdbfe2b8fa claim: HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP at the 2026-06-02 meeting. evidence_excerpt: Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: Votes For Votes Against Votes Abstained 2,781,705 13,975 3,849 evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.